Biovac Expansion Signals Africa’s Rising Role in Global Vaccine Manufacturing

The Biovac expansion forms part of the Department of Trade, Industry and Competition’s broader industrialisation strategy and its ongoing efforts to strengthen strategic manufacturing sectors within South Africa’s economy.

Africa is increasingly positioning itself as a producer, innovator, and strategic partner in global healthcare manufacturing, South African Trade, Industry and Competition Minister Parks Tau has said during the groundbreaking ceremony for the expansion of Biovac's vaccine manufacturing facility in Cape Town.

The expansion of the Biovac Pharma facility marks a significant milestone in South Africa's pharmaceutical industrialisation efforts and reflects broader ambitions to strengthen Africa's healthcare sovereignty, vaccine manufacturing capabilities, and regional industrial resilience.

Biovac Expansion Strengthens Africa's Vaccine Manufacturing Capacity

Biovac, a South African biopharmaceutical company established in 2003 through a partnership with the government, was created to build local vaccine manufacturing capabilities and reduce dependence on imported vaccines.

Speaking at the sod-turning ceremony, Minister Tau said the project sends a strong message globally that Africa is no longer merely a consumer of healthcare products but is emerging as a strategic manufacturing and innovation hub.

He emphasized that the COVID-19 pandemic exposed major vulnerabilities in Africa's dependence on imported vaccines, medical devices, pharmaceuticals, and diagnostic technologies.

According to the Minister, the pandemic demonstrated the urgent need for African countries to strengthen local manufacturing capabilities in order to improve:

• Health security

• Pandemic preparedness

• Medical self-reliance

• Regional supply chain resilience

• Access to essential healthcare products

Tau stated that South Africa has both the responsibility and capability to play a leading role in advancing the continent's healthcare manufacturing agenda despite ongoing challenges and high import dependence.

Expansion Linked to Industrialisation Strategy

The Biovac expansion forms part of the Department of Trade, Industry and Competition's broader industrialisation strategy and its ongoing efforts to strengthen strategic manufacturing sectors within South Africa's economy.

Officials said the project directly contributes to several national industrial development objectives, including:

• Expanding local pharmaceutical manufacturing

• Enhancing advanced production capabilities

• Supporting technology transfer

• Strengthening innovation ecosystems

• Creating high-skilled employment opportunities

• Deepening industrial localisation efforts

The project is also aligned with the African Union's health sovereignty ambitions, particularly the Partnerships for African Vaccine Manufacturing initiative and the African Continental Free Trade Area (AfCFTA) strategy aimed at building regional industrial value chains across Africa.

Cape Town Facility to Produce Critical Vaccines

The expanded Biovac facility in Cape Town is expected to manufacture vaccines for several critical diseases, including:

• Cholera

• Polio

• Pneumonia

• Meningitis

Once operational, the facility is projected to produce between 30 million and 40 million vaccine doses annually. The project is expected to be completed by 2028.

The expansion is also expected to create:

• More than 340 skilled direct jobs

• Approximately 7,000 indirect employment opportunities

Industry experts believe the project could significantly strengthen Africa's ability to respond to future health emergencies while reducing reliance on overseas vaccine suppliers.

Government Emphasizes Public-Private Collaboration

Minister Tau reiterated the South African government's commitment to creating an enabling environment for advanced manufacturing industries through:

• Localisation policies

• Investment incentives

• Skills development programs

• Innovation support mechanisms

• Stronger public-private partnerships

He also acknowledged the role played by multiple international financial and development institutions supporting the project, including:

• European Investment Bank

• International Finance Corporation

• Proparco

• Industrial Development Corporation

• European Commission

• GAVI, the Vaccine Alliance

• African Vaccine Manufacturing Accelerator (AVMA)

The African Vaccine Manufacturing Accelerator alone represents a $1.2 billion, 10-year funding initiative designed to support African vaccine manufacturers in achieving long-term sustainability.

European Union Backs African Health Security

The European Union has emerged as one of the major international supporters of the Biovac expansion project.

David McAllister, Chairperson of the European Parliament's Foreign Affairs Committee, highlighted that Team Europe's €95 million contribution represents the largest financing package in Biovac's history.

He described the investment as an important example of the EU's Global Gateway strategy in Africa, aimed at strengthening health security, reducing external dependencies, and building industrial resilience across the continent.

McAllister emphasized that the project goes beyond financing and will contribute to:

• Skilled job creation

• Industrial value chain development

• Local beneficiation

• EU-Africa private sector partnerships

• Regional manufacturing capabilities

Biovac CEO Highlights Importance of Local Support

Biovac Chief Executive Officer Dr Morena Makhoana stressed the symbolic importance of the South African government's participation in the project.

He stated that while Biovac benefits from global partnerships involving technology transfer, financing, and product development, strong domestic support remains irreplaceable.

According to Dr. Makhoana, the project demonstrates that South Africa's local ecosystem, led by government support, is fully committed to helping Biovac become a globally competitive end-to-end vaccine manufacturer.

Africa's Push for Health Sovereignty

The Biovac expansion reflects a broader continental push toward achieving greater healthcare independence and pharmaceutical manufacturing capacity.

Africa currently imports a significant portion of its vaccines and medical products, leaving many countries vulnerable during global health crises and supply chain disruptions.

The African Union's Vision 2040 aims to increase local vaccine production in Africa to 60 percent, reducing dependence on imported vaccines and strengthening regional healthcare resilience.

Experts believe investments like Biovac could become critical building blocks for:

• Regional pharmaceutical ecosystems

• Research and development capabilities

• Advanced biotechnology industries

• Health emergency preparedness

• Sustainable healthcare supply chains

Industrial Development and Public Health Interconnected

Minister Tau emphasized that projects such as the Biovac expansion demonstrate the strong connection between industrial development and public health security.

Analysts note that the future of healthcare resilience increasingly depends on domestic manufacturing capacity, scientific innovation, and regional industrial integration.

The project is also aligned with several United Nations Sustainable Development Goals and has been identified as a flagship initiative under the EU-South Africa Comprehensive Trade and Investment Partnership as well as South Africa's 3D Industrial Policy framework.

With vaccine manufacturing becoming strategically important worldwide after the COVID-19 pandemic, South Africa's efforts to strengthen its pharmaceutical and biotechnology industries may position the country as one of Africa's leading healthcare manufacturing hubs in the coming years.